📰 John Mullaly News
John Mullaly News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from John Mullaly. Real-time updates on events, politics, business and more.
January 2, 2024
The current market for breast implants is estimated at $2.6 billion a yearCollPlant expects the study to conclude by the first half of 2024CollPlant plans to use findings from this study and...
December 26, 2023
NEW YORK, Dec. 26, 2023 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today provided an update on the grant...
December 18, 2023
REDWOOD CITY, Calif., Dec. 18, 2023 -- Jasper Therapeutics, Inc. , a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit in mast cell-driven...
December 12, 2023
SEATTLE, Dec. 12, 2023 -- Kineta, Inc. , a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced...
December 10, 2023
REDWOOD CITY, Calif., Dec. 10, 2023 -- Jasper Therapeutics, Inc. , a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit to address mast cell...
December 7, 2023
Meeting Provided a Clear Path for Planned Phase 3b Trial NEW YORK, Dec. 7, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for...
November 1, 2023
- Intellectual Property Rights Secured in One of the Largest Target Markets for CollPlants Potential Products - REHOVOT, Israel, Nov. 1, 2023 /PRNewswire/ -- CollPlant Biotechnologies , a...
October 27, 2023
CAMBRIDGE, Mass. and NESS ZIONA, Israel, Oct. 27, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target
October 18, 2023
- Path forward for ALS is a registrational Phase 3b U.S. clinical trial - - Biologics License Application to be withdrawn without prejudice - - Conference call and webcast at 8:30am ET today...
October 9, 2023
SEATTLE, Oct. 09, 2023 -- Kineta, Inc. , a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced...